Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 07, 2026.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores Pharmaceuticals' Board, meeting on January 7, 2026, approved issuing up to 11,70,000 fully convertible equity warrants to members of its Promoter and Promoter Group via a preferential issue. Each warrant (face value ₹10) carries an exercise price of ₹812, aggregating to approximately ₹95 crore and representing 2.48% of the fully diluted paid-up capital. The five allottees are Swapnil Jatin Shah, Renosen Pharmaceuticals Pvt Ltd, Ashokbhai Vijaysinh Barot, Sangeeta Mukur Barot, and Viraj Ashokkumar Barot. Upon full conversion, promoter group holding will rise from 23.36% to 25.26%. Warrants carry an 18-month tenor, require 25% upfront payment, and the balance on conversion. An EGM is scheduled for January 31, 2026, to seek shareholder approval.
This is a capital infusion from existing promoters rather than outside investors, increasing promoter stake by about 1.9 percentage points. The minor dilution (~2.48%) and promoter-led funding signal confidence, though the warrants are unlisted and could exert mild supply pressure on conversion if exercised in the future.